EYA2 Inhibitors
EYA2 inhibitors represent a class of chemical compounds specifically designed to target and impede the activity of the EYA2 protein. The EYA2 gene encodes for Eyes Absent Homolog 2, a member of the Eyes Absent (EYA) family of proteins that play crucial roles in cellular development and differentiation. The EYA proteins are characterized by their dual functionality as both transcriptional coactivators and phosphatases, and they are involved in various signaling pathways crucial for embryonic development and tissue homeostasis.
Chemically, EYA2 inhibitors are designed to interact selectively with the active site of the EYA2 protein, disrupting its enzymatic activity. By inhibiting EYA2, these compounds modulate the dephosphorylation of target substrates and thereby influence downstream signaling cascades. The structural diversity within the class of EYA2 inhibitors allows for tailored design strategies to optimize binding affinity and selectivity. Researchers employ various medicinal chemistry approaches, including rational drug design and high-throughput screening, to identify and develop small molecules capable of inhibiting EYA2 with precision. Understanding the structural and functional nuances of EYA2 inhibition is essential for elucidating its biological impact and exploring potential applications in basic research contexts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can indirectly affect EYA2 by altering phosphorylation cascades. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin, a flavonoid, can modulate kinase activity and might influence the signaling pathways that regulate EYA2. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a BCR-ABL tyrosine kinase inhibitor that may indirectly affect EYA2 signaling in related pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that may disrupt downstream signaling affecting EYA2 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that might alter the signaling pathways interacting with EYA2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could modify pathways potentially involving EYA2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a broad spectrum kinase inhibitor, can alter multiple signaling pathways that might intersect with EYA2. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF kinase inhibitor that might affect signaling cascades related to EYA2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can influence the signaling pathways EYA2 is involved in. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can disrupt EYA2-related signaling pathways. | ||||||